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 Abstract: Here, we report the case of a 30-year old woman with relapsed AML who was treated 
with all-trans retinoic acid (ATRA) as part of investigational therapy (NCT02273102). The patient 
died from rapid disease progression following eight days of continuous treatment with ATRA. 
Karyotype analysis and RNA-Seq revealed the presence of a novel t(4;15)(q31;q22) reciprocal 
translocation involving the TMEM154 and RASGRF1 genes. Analysis of primary cells from the 
patient revealed expression of TMEM154-RASGRF1 mRNA and the resulting fusion protein but no 
expression of the reciprocal RASGRF1-TMEM154 fusion. Consistent with the response of the patient 
to ATRA therapy, we observed a rapid proliferation of t(4;15) primary cells following ATRA 
treatment in vitro. Preliminary characterisation of the retinoid response of t(4;15) AML revealed 
that, in stark contrast to non-t(4;15) AML, these cells proliferate in response to specific agonists of 
RARα and RARγ. Furthermore, we observed an increase in the levels of nuclear RARγ upon ATRA 
treatment. In summary, the identification of the novel t(4;15)(q31;q22) reciprocal translocation 
opens new avenues in the study of retinoid resistance and provides potential a new biomarker for 
therapy of AML. 
  
 1. Introduction 
Acute myeloid leukemia (AML) is the most commonly occurring leukemia in adults, accounting 
for an estimated 33% of all cases and more that 80% of acute cases in 2016 [1]. AML is a disease 
whose incidence increases with age and, in line with an aging population, this has increased from 3.4 
per 100,000 in 2004 to 5.1 per 100,000 in 2013 [2]. Advances in the treatment of AML have 
dramatically improved treatment outcomes for younger patients with a relative 5-year survival rate 
(2005-2011) of approximately 67% (0-14 years) [1]. In the elderly, however, who account for the 
majority of new cases, the prognosis remains poor. Indeed, AML accounts for an estimated 43% of all 
leukemia deaths, with an overall average 5-year survival rate of only 27% [2]. 
The use of combination therapy based on the use all-trans retinoic acid (ATRA) and arsenic 
trioxide (As2O3) has revolutionized the clinical outcome of acute promyelocytic leukemia (APL), with 
complete remission rates of 90% and cure rates of around 80% [3]. The success of ATRA-based 
therapy in AML has, however, not been translated into other non-APL subtypes of AML. Based on in 
vitro data showing efficacy with cytotoxic chemotherapy agents, such as Ara-C and anthracyclines 
several clinical studies have investigated the impact of adding ATRA to chemotherapy in patients 
with non-APL AML [4]. Unfortunately, however, these studies have yielded inconsistent and 
conflicting results. One possible reason for a lack of response to ATRA treatment in non-APL AML 
patients is epigenetic repression of the retinoic acid receptor pathway, especially the RARA gene [5]. 
Indeed, combination therapy of ATRA with epi-drugs targeting the histone H3 lysine 4 demethlyase 
LSD1 (KDM1A) has shown promise in in vivo models of AML [6]. This approach is now being 
evaluated in a phase I clinical trial where patients are given escalating doses of the LSD1 inhibitor 
Parnate (tranylcypromine, TCP) with fixed continuous doses of ATRA. 
Acute myeloid leukemia (AML) is characterized by clonal or oligoclonal hematopoiesis that 
varies amongst patients. On average, at least 4-5 oncogenic mutations or chromosomal abnormalities 
are present at diagnosis, along with passenger mutations of unclear significance [7]. Clonal evolution 
occurs after exposure to chemotherapy and the secondary mutations that give rise to these clones are 
more likely to be random, as opposed to recurrent primary abnormalities [8]. We report here a case of 
relapsed AML characterised by a previously unidentified chromosomal translocation. 
2. Results 
2.1 Clinical presentation 
A 30-year-old, previously healthy African-American female, presented with a white blood cell 
count (WBC) of 180,000/µl, haemoglobin 7.6 g/dl, platelets 93,000/µl. Physical examination was 
unremarkable. Bone marrow aspiration and biopsy were consistent with AML with monocytic 
differentiation. Blasts amounted to 95% of nucleated elements and expressed CD34, CD117, CD13, 
CD33, CD64 (weak), CD38, HLA-DR and were negative for TdT and MPO by flow cytometry. 
Cytogenetic analysis revealed an abnormal female karyotype: 46,XX,t(9;11)(p22;q23)[13]/46,XX[7]. 
Additionally, mutational analysis revealed an activating mutation in NRAS gene (c.34G>A; p.G12S). 
Following treatment with standard therapy, the patient achieved complete cytogenetic remission. Post 
remission therapy followed, with sequential cycles of high dose cytarabine in the absence of an 
optimal donor. Following a disease-free interval of 8 months, the patient relapsed. Karyotype at 
relapse was consistent with clonal evolution: 46,XX,t(4;15)(q31;q22), t(9;11)(p22;q23)[20] (Figure 
1A). Mutational analysis confirmed the presence of an NRAS mutation as before. The patient failed 2 
lines of salvage chemotherapy. In the setting of chemotherapy refractory disease, the patient was 
enrolled on the phase I clinical trial (NCT02273102) and given escalating doses of TCP with fixed 
continuous doses of ATRA. However, the patient died from rapid disease progression after eight days 
of treatment (WBC at screening was 400/µl and at withdrawal from study WBC was 99,300/µl). 
2.2 Molecular and functional characterization of the t(4;15) fusion gene 
To characterize the translocation partners and their breakpoints, we used RNA-Seq and Sanger 
sequencing, confirming the t(9;11) MLL(KMT2A)-AF9(MLLT3) reciprocal translocation present at 
diagnosis (data not shown). We also defined a novel fusion gene comprising exons 1-6 of the 
TMEM154 gene (4q31.3) and exons 15-24 of the RASGRF1 gene (15q24.2) (Figure 1B). This 
generates a putative 830 amino acid TMEM154-RASGRF1 fusion protein comprising amino acids 1-
178 of TMEM154 and 622-1273 of RASGRF1 (Figure 1C). RT-PCR analysis confirmed the 
presence of TMEM154-RASGRF1 mRNA in t(4;15) AML cells but not normal controls (Figure 1D, 
lanes 1-2 and 5-6). By contrast, controls for TMEM154 were present in both t(4;15) AML cells and 
normal controls (Figure 1D, lanes 4 and 8). Consistent with the RNA-Seq results, expression of 
mRNA transcripts arising from the reciprocal RASGRF1-TMEM154 fusion gene were not detected in 
t(4;15) AML cells (Figure 1D, lane 3).  
 
Figure 1. Analysis of the t(4;15)(q31;q22) reciprocal chromosomal translocation. (A) 
Conventional karyotyping showing 46,XX, t(4;15)(q31;q22), outlined in red and t(9;11) 
(p22;q23), outlined in blue. Chromosome analysis was performed on 20 G-banded 
metaphase cells from multiple unstimulated cultures. Both translocations were present in all 
cells examined. (B) Breakpoint analysis of the novel fusion transcript produced by the 
t(4;15) chromosomal translocation. TMEM154 and RASGRF1 form a chimeric mRNA 
transcript with breakpoints as indicated. (C) Sanger sequencing chromatogram showing the 
transcribed sequence surrounding the breakpoint. (D) PCR analysis of and TMEM154-
RASGRF1, RASGRF1-TMEM154 and TMEM154 transcripts. PCR was performed on t(4;15) 
AML cells (lanes 1-4) and bone marrow mononuclear cells (BM-MNC) from a healthy 
donor (lanes 5-8). Bands correspond to a 445 bp product amplified fromTMEM154-
RASGRF1 mRNA (lanes 1 and 5), a 589 bp product amplified fromTMEM154-RASGRF1 
mRNA (lanes 1 and 5) and a 445 bp product amplified fromTMEM154 mRNA (lanes 4 and 
8). No product was amplified using primers corresponding to RASGRF1-TMEM154 mRNA 
(lanes 3 and 7).  
 
Figure 2. Characterization of t(4;15) AML primary cells. (A) Immunoblot analysis of 
TEM154-RASGRF1 expression. After 72 hours treatment, vehicle control non-t(4;15) AML 
cells (lane 1), vehicle control t(4;15) AML cells (lane 2) and ATRA t(4;15) AML cells (lane 
3) were subjected to immunoblot analysis. Samples were probed with rabbit monoclonal 
antibody against a C-terminal region of RASGRF1 and mouse monoclonal antibody against 
a N-terminal region of TMEM154. β-actin was used as a loading control. Molecular weight 
standards (left) and the identities of bands (right) are indicated. (B) Proliferation of t(4;15) 
AML cells in response to retinoids. Cells were treated with vehicle control, ATRA, RARα 
agonist (AM-80 or AGN-195183), or RARγ agonist (AGN-205327). Cells were also treated 
with RARα antagonist (AGN-196996), RARγ antagonist (AGN-205728) or RARα/β/γ 
antagonist (AGN-194310). All retinoids were used at a concentration of 1 µM. Cell 
proliferation was determined by CellTiter-Glo luminescent cell viability assay (Promega) 
after 72 hours of treatment. Values shown are normalized to vehicle control. (C) 
Proliferation of t(4;15) and non-t(4;15) AML cells in response to retinoid agonists. Samples 
from t(4;15) and 7 non-t(4;15) AML patients were incubated with vehicle control, ATRA, 
RARα agonist (AGN-195183), or RARγ agonist (AGN-205327) at a concentration of 1 µM. 
Cells were analysed and normalized as described for (B). (D) Treatment of t(4;15) cells with 
ATRA increases levels of nuclear RARγ. t(4;15) cells were treated with vehicle control or 1 
µM ATRA and incubated for 72 hours before staining with RARα mouse monoclonal and 
RARγ rabbit polyclonal antibodies.  
In agreement with our analysis of mRNA expression, Western blot analysis revealed expression 
of endogenous TMEM154 and RASGRF1 proteins, as well as TMEM154-RASGRF1 fusion protein, 
which could be detected using antibodies directed against both a N-terminal region of TMEM154 as 
well as a c-terminal region of RASGRF1 (Figure 2A). Interestingly, treatment with ATRA led to an 
increase in expression of TMEM154-RASGRF1 fusion protein but not endogenous TMEM154 or 
RASGRF1(Figure 2A). Supporting the clinical history, we observed a rapid proliferation of the 
patient’s blasts following treatment with ATRA in vitro (Figure 2B). The same phenotype was seen 
when the cells were exposed to other agonists of the retinoic acid pathway. Primary cells lacking a 
t(4;15)(q31;q22) rearrangement displayed no growth alteration compared to controls when treated 
with either ATRA (a pan-RAR isotype agonist) or isotype selective agonists specific for RARα or 
RARγ (Figure 2C). To further examine the effects of ATRA on primary t(4;15) AML cells, we 
performed immunofluorescence analysis of RARα or RARγ. Here, we found that treatment of t(4;15) 
AML cells with ATRA led to an increase in nuclear RARγ (Figure 2D). 
3. Discussion 
Our data suggest that the t(4;15)(q31;q22) reciprocal translocation confers a growth-stimulatory 
response to retinoid-based therapy. The basis for this response requires further investigation but could 
lie, at least in part, to an increase in nuclear RARγ following ATRA treatment. While RARα is 
required for myeloid differentiation, RARγ has been shown to promote hematopoietic stem and 
progenitor cell self-renewal and proliferation [9]. Additionally, it is likely that the ATRA-mediated 
increase in TMEM154-RASGRF1 fusion protein (which is consistent with established ATRA 
regulation of TMEM154 [14]) cooperates with mutant NRAS G12S (which results in decreased 
GTPase activity and constitutive RAS signalling). Between 12-19% of AML patients possess gain-of-
function mutated RAS genes [7], with NRAS being most frequently affected [10]. Furthermore, other 
components of the RAS pathway signalling cascade are often mutated [11]. RASGRF1 (RAS protein 
specific nucleotide releasing factor 1) is a guanine nucleotide exchange factor (GEF) similar to the 
Saccharomyces cerevisiae CDC25 gene product and functions to activate RAS by catalyzing the 
exchange of RAS-bound GDP for GTP [12]. While we have not yet investigated the activity of 
TMEM154-RASGRF1 towards NRAS, it is noteworthy that the fusion protein (which lacks 
regulatory domains contained in N-terminal RASGRF1) contains the membrane anchoring domain of 
TMEM154 and functional domains of RASGRF1. These include the GDP/GTP RAS exchanger and 
CDC25H motifs of RASGRF1, which have been shown to be sufficient for functional protein [13]. 
Another aspect of the consequences of the t(4;15) translocation that merits further consideration 
is the fact that RASGRF1 is a paternally expressed imprinted gene. Thus, under normal conditions 
only the paternal allele of the gene is translated into protein. In t(4;15) AML both the TMEM154-
RASGRF1 fusion protein as well endogenous RASGRF1 are expressed, leading to possible gene 
dosage effects. Conversely, the lack of expression of the reciprocal RASGRF1-TMEM154 indicates 
that the differentially methylated domain (DMD) located 30 kb 5′ of the RASGRF1 transcription 
initiating site [15] is intact, resulting in imprinted methylation. A functionally important consequence 
of this could be inappropriate silencing of genes downstream of TMEM154. Here, it is noteworthy that 
the gene immediately downstream of TMEM154 is FBXW7, which encodes an F-box family protein 
that is a component of the SCF (SKP1-cullin-F-box) ubiquitin protein ligase complex. In the context 
of AML, FBXW7 has clinically relevant targets including MYC, MCL-1 and Cyclin E [16, 17]. 
4. Materials and Methods  
4.1 Patient Samples 
Primary AML samples were collected by the Tissue Banking Core Facility (TBCF) at the 
University of Miami according to an institutional review board (IRB) approved protocol (20060858). 
In order to purify the mononuclear fraction, bone marrow aspirates were subjected to density gradient 
centrifugation using Ficoll Paque Plus (GE Healthcare Life Sciences). 
4.2 DNA/RNA isolation 
DNA and RNA were isolated from mononuclear cells from patient’s bone marrow aspirate. DNA 
was isolated using QIAamp DNA Mini Kit (Qiagen) according to manufacturer’s instructions. RNA 
was extracted with PureLink RNA kit (Life Technologies) following manufacturer’s 
recommendations. 
4.3 RNA Seq for Breakpoint identification 
Preparation of RNA libraries for sequencing on the Illumina HiSeq2500 platform was carried out 
in the John P. Hussman Institute for Human Genomics Center for Genome Technology at the 
University of Miami. Briefly, total RNA was quantified and qualified by Agilent Bioanalyzer to have 
an RNA integrity score (RIN) of 7. For each of the two samples, 1000ng of total RNA was used as 
input for the Illumina TruSeq Stranded Total RNA Library Prep Kit with Ribo-Zero to create 
ribosomal RNA depleted sequencing libraries. Each sample was barcoded to allow for multiplexing 
and was sequencing to ~30 million raw reads in a 2x125 paired end sequencing run on an Illumina 
HiSeq2500.Raw sequence data from the Illumina HiSeq2500 was processed by the on-instrument 
Real Time Analysis software (v.1.8) to basecall files. These were converted to demultiplexed FASTQ 
files with the Illumina supplied scripts in the BCL2FASTQ software (v1.8.4). The quality of the reads 
was determined with FastQC software for per base sequence quality, duplication rates, and 
overrepresented kmers (www.bioinformatics.babraham.ac.uk/projects/fastqc/). Illumina adapters were 
trimmed from the ends of the reads using Trim Galore! resulting in two trimmed FASTQ files per 
sample (http://www.bioinformatics.babraham.ac.uk/projects/trim_galore/). Reads were aligned to the 
human reference genome (hg19) with the STAR aligner (v2.5.0a) [18]. Gene fusions were detected in 
the aligned BAM files using the Manta software [19]. 
4.4 Accession Numbers 
The Genbank accession number for TMEM154-RASGRF1 mRNA is MF175878. RNA-Seq 
FASTQ files were submitted to the sequence read archive (SRA) with the Genbank accession number 
SRR5681084. 
4.5 RT-PCR 
Reverse transcription and PCR amplification was performed using One-Step RT-PCR System 
(Life Technologies) according to manufacturer’s instructions. Primers used to amplify TMEM154-
RASGRF1 mRNA were TMEM154-Fwd333: 5’-TAGCCAAGGATCTCAGAGTG-3’; and 
RASGRF1-Rev778: 5’-GAATGGCACTGATAGGCTTC-3’ or RASGRF1-Rev922: 5’-
GTGACGATGTCTTGGTGATG-3’. Primers used to amplify TMEM154 were TMEM154-Fwd1762: 
5’-TAGCCAAGGATCTCAGAGTG-3’ and TMEM154-Rev2272: 5’-
TGAGCGCCATTCAGGTTTAG-3’. Primers to amplify RASGRF1-TMEM154 were RASGRF1-
Fwd1762: 5’-CTCATTCAGGTGCCCATGTC-3’ and TMEM154-Rev2272: 5’-
TGAGCGCCATTCAGGTTTAG-3’. Amplified PCR fragments were subjected to DNA sequence 
(Eurofins) to validate the translocation breakpoint. 
4.6 Western blot 
Protein sample concentrations were normalized using DC Protein Assay (Bio-Rad). 50 µg of 
protein were separated by SDS-PAGE using 4–20% Mini-PROTEAN TGX pre-cast gels with 
Precision Plus ProteinDual Color Standards (Bio-Rad). Primary antibodies used were as follows: 
rabbit monoclonal antibody against the C-terminal region of RASGRF1 (Abcam, ab118830) and 
mouse monoclonal antibody against the N-terminal region of TMEM154 (Santa Cruz Biotechnology, 
sc-398802). β-actin was used as a loading control (Sigma, A5441). Protein bands were detected using 
HRP-linked Anti-rabbit IgG (Cell Signaling Technology, #7074) and HRP-linked Anti-mouse IgG 
(Cell Signaling Technology, #7076) secondary antibodies. 
4.7 Cell proliferation 
Cell proliferation was measured using CellTiter-Glow luminescent cell viability assay (Promega) 
following the manufacturer’s recommendations. Primary AML mononuclear cells were seeded at a 
density of 10,000 cells/well in a 96-well plate for 24 hours, followed by retinoid or vehicle (DMSO) 
treatment for 72 hours. Cell were cultured in RPMI supplemented with 5% Charcoal-dextran FBS 
(Life Technologies). ATRA was purchased from Sigma. AM-80 was purchased from Tocris 
Bioscience. AGN195183, AGN196996, AGN205327, AGN205728 and AGN194310 were 
manufactured under contract at the Chinese National Center for Drug Screening, Shanghai Institute of 
Materia Medica, Shanghai, China. 
4.8 Immunofluorescence 
AML cells were fixed with 4% paraformaldehyde in 1X PBS for 20 minutes at room 
temperature. For immunostaining, cells were permeabilized with 1% Triton X-100 in 1XPBS and 
blocked with 2.5% BSA and 1% Triton X-100 in 1X PBS for 1 hour shaking at room temperature. 
Primary antibodies (dilution 1:100) were incubated for 2 hours at room temperature in blocking buffer 
and washed 5 times with wash buffer (0.1% Triton X-100 in 1X PBS). Primary antibodies used were 
RARα-9a (mouse monoclonal) and RARγ-453 (rabbit polyclonal) (gift from Dr. Cécile Rochette-
Egly, L'Institut de Génétique et de Biologie Moléculaire et Cellulaire (IGBMC), France). Secondary 
antibodies (dilution 1:1000) were added for 1 hour at room temperature in blocking buffer and then 
washed 5 times. Secondary antibodies used were Alexa Fluor 488-conjugated anti-mouse IgG (H+L), 
F(ab')2 fragment (Cell Signaling Technology, #4408) and Alexa Fluor 555-conjugated anti-rabbit IgG 
(H+L), F(ab')2 fragment (Cell Signaling Technology, #4413). Slides were then mounted with 
ProLong Gold antifade reagent with DAPI (Molecular Probes), following the manufacturer 
instructions. Immunofluorescence microscopy was performed using a Leica DFC 310 FX microscope. 
5. Conclusions 
We report here a case of relapsed AML characterised by a novel translocation associated with 
aggressive disease and increased proliferation in the presence of ATRA. We are currently generating a 
cell line bearing this translocation that will provide a new model system for the study of AML. 
Although the TMEM154-RASGRF1 translocation is likely to be a rare occurrence, as has been the 
case in the past with other translocations, it is predicted that further study of its biology will yield 
important insights into retinoic acid signalling and resistance to retinoid-based therapy in AML. 
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